logo
Nottingham Forest exploring possible deal for Aston Villa's Matty Cash

Nottingham Forest exploring possible deal for Aston Villa's Matty Cash

New York Times12 hours ago
Nottingham Forest are exploring a deal to re-sign Aston Villa right-back Matty Cash.
The 28-year-old is among Forest's options as they look to strengthen the right side of defence. The club have also been pursuing a deal for Manchester City's Rico Lewis.
Villa have not received a formal approach, with the defender's current contract, which he signed in April 2022, running until 2027. There have been discussions over extending his stay in recent months.
Advertisement
A move to the City Ground would see Cash return to the club where he began his senior career and made 141 appearances, scoring 13 goals and providing 14 assists. The defender's current Villa contract, which he signed in April 2022, runs until 2027.
Cash left Forest, then a Championship club, to join Villa in a £14m deal, with potential add-ons, in 2020.
His salary would make it a potentially challenging deal for Forest, but he would be a cheaper all-round package than Lewis, who would command a much higher fee and stated publicly at the weekend he would like to stay at City.
The defender started Villa's first game of the 2025-26 campaign, a 0-0 draw with Newcastle United on Saturday, and made 38 appearances last season under Unai Emery.
Villa's transfer activity this summer has been stifled by various financial sanctions, such as the UEFA Squad Cost Rule (SCR), which states that a club can only spend up to 71 per cent of overall revenue on player salaries. Villa have had to be mindful of this, having had a previous wage to turnover ratio of 91 per cent.
As well as this, Villa's need to sell was underlined by the departure of homegrown midfielder, Jacob Ramsey, who joined Newcastle. Villa also have to comply with UEFA's Football Earnings Rule as this season will be their third successive campaign in European competition and thereby need to comply with the rule that states they cannot lose over €60million across that period.
This is tighter than the Premier League's Profit and Sustainability Rules (PSR), which permits losses of up to £105million over three years.
Ramsey's departure has been followed by other players, including Leander Dendoncker to Real Oviedo and Leon Bailey, who is set to join AS Roma on a season-long loan with an option to make the move permanent. Villa hope to add players once they are compliant and are targeting a defender and an attacker.
Advertisement
Cash spent time in Wycombe Wanderers' academy as a teenager before joining Forest in 2014. He had a one-month loan spell at Dagenham and Redbridge in 2016 before making his senior Forest debut in August of that year.
He joined Villa in September 2020 and has gone on to record 10 goals and 12 assists in 181 appearances for the club, helping the side qualify for the Champions League with a fourth-place league finish in the 2023-24 season.
Born in England, Cash represents Poland at international level and has been capped 19 times, appearing at the 2022 World Cup in Qatar.
Forest have been active in the transfer market this summer, securing the arrivals of Dan Ndoye from Bologna, Jair Cunha and Igor Jesus from Botafogo, Omari Hutchinson from Ipswich Town, James McAtee from City, Arnaud Kalimuendo from Rennes and Angus Gunn as a free agent.
()
Spot the pattern. Connect the terms
Find the hidden link between sports terms
Play today's puzzle
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Villarreal agree personal terms with Chelsea star
Villarreal agree personal terms with Chelsea star

Yahoo

time17 minutes ago

  • Yahoo

Villarreal agree personal terms with Chelsea star

La Liga outfit Villarreal have reached an agreement on the personal terms of a contract with a member of the defensive ranks at Premier League giants Chelsea. That's according to transfer insider Fabrizio Romano, who points towards Renato Veiga as the player in question. Defender Veiga is for his part expected to be on the move before the summer transfer window is out. This comes with the Portuguese, fresh off a solid loan stint with Juventus over the 2nd half of last season, not featuring in the plans of Chelsea boss Enzo Maresca. Held in high regard across the continent, a number of bids, in turn, are understood to have been tabled for Veiga of late. And as alluded to above, this week, one of the 22-year-old's many suitors have found an agreement with the player himself. As per a report from journalist Fabrizio Romano: 'Villarreal have agreed personal terms with Renato Veiga! Talks are well underway with Chelsea. The Spanish club is negotiating to agree on terms also with Chelsea. Current proposal: €24m plus add-ons, trying to get closer to €30m package.' Conor Laird – GSFN

Milan can close move for Bayer Leverkusen's Victor Boniface tomorrow
Milan can close move for Bayer Leverkusen's Victor Boniface tomorrow

Yahoo

time17 minutes ago

  • Yahoo

Milan can close move for Bayer Leverkusen's Victor Boniface tomorrow

Serie A giants Milan can close their move for Bayer Leverkusen striker Victor Boniface as early as tomorrow. The Rossoneri made a move for the player earlier today, after having been linked with a host of strikers in the last two weeks. MilanNews report that work is ongoing at Milan to close a deal for Boniface quickly and talks have now advanced quickly with Bayer Leverkusen. Some steps are remaining to finalise the deal and Milan are very confident of signing the player and the move can close as early as tomorrow. Max Allegri's side will sign the Nigerian for an initial loan deal with an option to buy for €30 million. Manchester United's Rasmus Hojlund was initially believed to be a key target but Napoli are making progress for the Dane now, even if Milan had been coming close to signing him over the last week or so. Kaustubh Pandey I GIFN

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Yahoo

time17 minutes ago

  • Yahoo

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, August 20, 2025 – Zealand Pharma A/S ('Zealand') (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 20 August 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 19 August 2025, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,115,191 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 9.973% of the total share capital and 9.973% of the total voting rights in Zealand Pharma A/S. Van Herk Investments B.V. is 100% owned by Van Herk Investments THI B.V., which is 100% owned by Van Herk Private Equity Investments B.V. (Dutch registration no. 58894543). Ultimately, Van Herk Private Equity Investments B.V. is owned and controlled by Mr. Adrianus van Herk. Van Herk Management Services B.V. (Dutch registration no. 24377325) controls and exercises the voting rights on behalf of Van Herk Investments B.V., and accordingly, Van Herk Management Services B.V controls and exercises the voting rights on nominally 7,115,191 shares (each share carrying one vote), corresponding to 9.973% of the total share capital and 9.973% of the total voting rights in Zealand Pharma A/S. Van Herk Management Services B.V., is controlled by OGBB A. van Herk B.V. (Dutch registration no. 24160906), which is controlled by A. van Herk Holding B.V. (Dutch registration no. 24160780), which is ultimately controlled by Mr. Adrianus van Herk. Please see further details in the attached notification forms. # # # About Zealand Pharma Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharmaceutical companies as well as commercial partnerships for its marketed was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit ContactAdam Lange (Investors) Vice President, Investor Relations alange@ Neshat Ahmadi (Investors) Investor Relations Manager neahmadi@ Anna Krassowska (Investors and Media) Vice President, Investor Relations & Corporate Communications akrassowska@ Attachments 20250819 FSA - Standardformular english Van Herk Investments BV_signed 20250819 FSA - Standardformular english Van Herk Management Services BV_signedError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store